Perceptive Advisors - Q4 2020 holdings

$9.32 Billion is the total value of Perceptive Advisors's 139 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 177.3% .

 Value Shares↓ Weighting
MRTX BuyMIRATI THERAPEUTICS INC$811,244,000
+42.2%
3,693,516
+7.5%
8.71%
+4.5%
NVTA NewINVITAE CORP$304,563,0007,284,466
+100.0%
3.27%
SWTX BuySPRINGWORKS THERAPEUTICS INC$302,968,000
+82.6%
4,177,721
+20.0%
3.25%
+34.2%
HZNP NewHORIZON THERAPEUTICS PUB L$225,597,0003,084,042
+100.0%
2.42%
RCKT BuyROCKET PHARMACEUTICALS INC$186,284,000
+272.3%
3,396,867
+55.2%
2.00%
+173.5%
NBIX BuyNEUROCRINE BIOSCIENCES INC$182,040,000
+22.2%
1,899,215
+22.6%
1.95%
-10.1%
NVRO BuyNEVRO CORP$169,217,000
+47.0%
977,565
+18.3%
1.82%
+8.1%
AVIR NewATEA PHARMACEUTICALS INC$129,903,0003,109,224
+100.0%
1.39%
NVAX BuyNOVAVAX INC$116,305,000
+51.7%
1,043,000
+47.4%
1.25%
+11.4%
FREQ BuyFREQUENCY THERAPEUTICS INC$114,935,000
+83.7%
3,259,635
+0.1%
1.23%
+35.0%
MGTX BuyMEIRAGTX HLDGS PLC$104,970,000
+23.2%
6,933,277
+7.8%
1.13%
-9.5%
CCCC NewC4 THERAPEUTICS INC$104,643,0003,158,566
+100.0%
1.12%
TVTX NewTRAVERE THERAPEUTICS INC$95,218,0003,493,607
+100.0%
1.02%
KRON NewKRONOS BIO INC$83,041,0002,780,097
+100.0%
0.89%
ARWR NewARROWHEAD PHARMACEUTICALS IN$82,164,0001,070,814
+100.0%
0.88%
SLDB BuySOLID BIOSCIENCES INC$81,893,000
+497.7%
10,803,857
+60.1%
0.88%
+339.5%
CHRS BuyCOHERUS BIOSCIENCES INC$81,197,000
+21.7%
4,671,836
+28.5%
0.87%
-10.6%
CERE NewCEREVEL THERAPEUTICS HLDNG I$75,340,0004,544,062
+100.0%
0.81%
ONCR NewONCORUS INC$64,336,0001,989,987
+100.0%
0.69%
PMVP BuyPMV PHARMACEUTICALS INC$54,471,000
+153.4%
885,556
+46.2%
0.58%
+86.3%
TARS NewTARSUS PHARMACEUTICALS INC$53,580,0001,296,416
+100.0%
0.58%
ADPT BuyADAPTIVE BIOTECHNOLOGIES COR$53,504,000
+32.6%
904,854
+9.0%
0.57%
-2.5%
UROV BuyUROVANT SCIENCES LTD$50,274,000
+127.4%
3,116,831
+31.7%
0.54%
+67.2%
SAGE NewSAGE THERAPEUTICS INC$38,064,000440,000
+100.0%
0.41%
COGT NewCOGENT BIOSCIENCES INC$35,810,0003,188,750
+100.0%
0.38%
NEPT BuyNEPTUNE WELLNESS SOLUTIONS I$34,655,000
-15.5%
22,214,683
+14.3%
0.37%
-37.9%
RAPT NewRAPT THERAPEUTICS INC$31,155,0001,577,481
+100.0%
0.33%
ISEE BuyIVERIC BIO INC$30,976,000
+57.8%
4,482,713
+28.8%
0.33%
+15.7%
VERU BuyVERU INC$28,113,000
+550.3%
3,250,000
+97.0%
0.30%
+379.4%
ACCD BuyACCOLADE INC$27,256,000
+139.2%
626,591
+113.8%
0.29%
+76.5%
REGN BuyREGENERON PHARMACEUTICALS$26,656,000
+852.3%
55,175
+1003.5%
0.29%
+597.6%
LUNG NewPULMONX CORP$26,573,000385,000
+100.0%
0.28%
ESTA BuyESTABLISHMENT LABS HLDGS INC$26,221,000
+108.5%
696,633
+2.7%
0.28%
+52.7%
ANAB NewANAPTYSBIO INC$25,700,0001,195,336
+100.0%
0.28%
FDMT New4D MOLECULAR THERAPEUTICS IN$24,881,000600,256
+100.0%
0.27%
ONEM Buy1LIFE HEALTHCARE INC$22,691,000
+185.9%
519,844
+85.8%
0.24%
+110.3%
NSTG NewNANOSTRING TECHNOLOGIES INC$22,592,000337,800
+100.0%
0.24%
VTRS NewVIATRIS INC$18,823,0001,004,419
+100.0%
0.20%
RGEN NewREPLIGEN CORP$18,684,00097,500
+100.0%
0.20%
SCYX NewSCYNEXIS INC$18,360,0002,400,000
+100.0%
0.20%
NBTX NewNANOBIOTIX SAsponsored ads$18,150,0001,100,000
+100.0%
0.20%
HRMY BuyHARMONY BIOSCIENCES HLDGS IN$18,170,000
+23.1%
502,622
+15.4%
0.20%
-9.3%
AMWL BuyAMERICAN WELL CORPcl a$13,298,000
-1.4%
525,000
+15.4%
0.14%
-27.4%
FBRX NewFORTE BIOSCIENCES INC$12,744,000350,000
+100.0%
0.14%
BLSA NewBCLS ACQUISITION CORP$11,140,0001,000,000
+100.0%
0.12%
CRIS NewCURIS INC$10,238,0001,250,000
+100.0%
0.11%
MRVI NewMARAVAI LIFESCIENCES HLDGS I$9,818,000350,000
+100.0%
0.10%
SHC NewSOTERA HEALTH CO$8,232,000300,000
+100.0%
0.09%
SNDX NewSYNDAX PHARMACEUTICALS INC$6,672,000300,000
+100.0%
0.07%
VINC NewVINCERA PHARMA INC$6,273,000300,000
+100.0%
0.07%
SGTX NewSIGILON THERAPEUTICS INC$6,004,000125,000
+100.0%
0.06%
PHR NewPHREESIA INC$5,426,000100,000
+100.0%
0.06%
CHFWU NewCONSONANCE HFW ACQUISITION Cunit 99/99/9999$5,235,000500,000
+100.0%
0.06%
MASS New908 DEVICES INC$4,414,00077,500
+100.0%
0.05%
AVXL NewANAVEX LIFE SCIENCES CORP$4,212,000780,007
+100.0%
0.04%
PTGX NewPROTAGONIST THERAPEUTICS INC$4,104,000203,591
+100.0%
0.04%
LSAQ NewLIFESCI ACQUISITION II CORP$3,201,000300,000
+100.0%
0.03%
VINCW NewVINCERA PHARMA INC*w exp 12/24/202$990,000300,000
+100.0%
0.01%
ABCL NewABCELLERA BIOLOGICS INC$805,00020,000
+100.0%
0.01%
IPOF NewSOCIAL CAPITAL HEDOSOPHIA HLD$671,00040,000
+100.0%
0.01%
DFHT NewDEERFIELD HEALTHCARE TECH AC$312,00020,000
+100.0%
0.00%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-16
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q4 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01
SC 13D/A2024-02-29
13F-HR/A2024-02-26
SC 13G/A2024-02-23
42024-02-21

View Perceptive Advisors's complete filings history.

Compare quarters

Export Perceptive Advisors's holdings